logo-loader

Summit Therapeutics PLC “optimist for the future” after latest ridinilazole phase II trial data

Published: 13:28 08 Mar 2016 GMT

Richard Pye, director of corporate communications at Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM), says he has been “really encouraged” by the data from the phase II trial for its new antibiotic for hospital superbug C.Diff.

Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.

The further positive data showed that ridinilazole can preserve the micobiome in the gut as it treats the condition.

“What is really gratifying is that what we’ve seen in the pre-clinical data is actually translating now into patients,” he says.

FTSE rises ahead of Easter weekend, JD Sport gains on upbeat outlook -...

The FTSE 100 gained on the final morning of this shortened Easter trading week. Festive cheer was limited though, as Thames Water confirmed shareholders would not provide it with a £500 million rescue package, prompting speculation over the London supplier’s future. On a more positive...

1 hour, 9 minutes ago